Toronto Dominion Bank increased its holdings in shares of ResMed Inc. (NYSE:RMD) by 13.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 61,142 shares of the medical equipment provider’s stock after acquiring an additional 7,216 shares during the period. Toronto Dominion Bank’s holdings in ResMed were worth $5,178,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. Pillar Pacific Capital Management LLC grew its position in shares of ResMed by 1.2% during the 4th quarter. Pillar Pacific Capital Management LLC now owns 43,755 shares of the medical equipment provider’s stock valued at $3,706,000 after acquiring an additional 540 shares during the period. Mutual of America Capital Management LLC grew its position in shares of ResMed by 3.6% during the 4th quarter. Mutual of America Capital Management LLC now owns 16,890 shares of the medical equipment provider’s stock valued at $1,430,000 after acquiring an additional 591 shares during the period. WINTON GROUP Ltd grew its position in shares of ResMed by 8.6% during the 3rd quarter. WINTON GROUP Ltd now owns 8,076 shares of the medical equipment provider’s stock valued at $622,000 after acquiring an additional 640 shares during the period. Advisor Group Inc. grew its position in shares of ResMed by 26.7% during the 3rd quarter. Advisor Group Inc. now owns 3,164 shares of the medical equipment provider’s stock valued at $244,000 after acquiring an additional 667 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in shares of ResMed by 3.2% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 22,600 shares of the medical equipment provider’s stock valued at $1,747,000 after acquiring an additional 700 shares during the period. Hedge funds and other institutional investors own 60.46% of the company’s stock.
Shares of ResMed Inc. (RMD) opened at $92.83 on Wednesday. ResMed Inc. has a twelve month low of $67.04 and a twelve month high of $104.78. The stock has a market capitalization of $13,407.99, a PE ratio of 46.42 and a beta of 0.92.
ResMed (NYSE:RMD) last posted its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.22. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The company had revenue of $601.27 million for the quarter, compared to analysts’ expectations of $583.77 million. During the same period in the previous year, the firm posted $0.73 EPS. ResMed’s revenue was up 13.4% compared to the same quarter last year. research analysts expect that ResMed Inc. will post 3.34 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 8th will be issued a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 1.51%. The ex-dividend date is Wednesday, February 7th. ResMed’s payout ratio is 70.00%.
In other ResMed news, Director John P. Wareham sold 25,934 shares of the firm’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $102.25, for a total value of $2,651,751.50. Following the transaction, the director now directly owns 38,934 shares of the company’s stock, valued at approximately $3,981,001.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Pendarvis sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $84.17, for a total transaction of $236,012.68. Following the completion of the transaction, the insider now directly owns 97,257 shares in the company, valued at $8,186,121.69. The disclosure for this sale can be found here. Insiders sold a total of 44,783 shares of company stock worth $4,420,848 over the last three months. Corporate insiders own 1.77% of the company’s stock.
A number of equities research analysts have recently commented on the company. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a research report on Friday, February 2nd. Needham & Company LLC upgraded ResMed from an “underperform” rating to a “hold” rating in a research report on Tuesday, January 23rd. BMO Capital Markets lifted their price objective on ResMed to $90.00 and gave the stock a “market perform” rating in a report on Tuesday, January 23rd. Northland Securities upgraded ResMed from an “under perform” rating to a “market perform” rating in a report on Tuesday, January 23rd. Finally, Macquarie cut ResMed from a “neutral” rating to a “sell” rating in a report on Tuesday, January 23rd. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company’s stock. ResMed presently has a consensus rating of “Hold” and an average target price of $74.83.
COPYRIGHT VIOLATION NOTICE: “Toronto Dominion Bank Has $5.18 Million Stake in ResMed Inc. (RMD)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2018/02/21/toronto-dominion-bank-has-5-18-million-stake-in-resmed-inc-rmd.html.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.